Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
8.49
+0.28 (3.41%)
At close: Sep 12, 2025, 4:00 PM EDT
8.45
-0.04 (-0.47%)
After-hours: Sep 12, 2025, 7:55 PM EDT

Company Description

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.

Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors.

Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Immuneering Corporation
Immuneering logo
CountryUnited States
Founded2008
IPO DateJul 30, 2021
IndustryBiotechnology
SectorHealthcare
Employees66
CEOBenjamin Zeskind

Contact Details

Address:
245 Main Street, Second Floor
Cambridge, Massachusetts 02142
United States
Phone617 500 8080
Websiteimmuneering.com

Stock Details

Ticker SymbolIMRX
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$15.00
CIK Code0001790340
CUSIP Number45254E107
ISIN NumberUS45254E1073
SIC Code2834

Key Executives

NamePosition
Dr. Benjamin J. Zeskind M.B.A., Ph.D.Co-Founder, President, Chief Executive Officer and Director
Robert J. Carpenter M.B.A., M.S.Co-Founder and Chair Emeritus
Dr. Brett M. Hall Ph.D.Chief Scientific Officer
Michael D. Bookman J.D.Chief Legal Officer and Secretary
Mallory Morales CPAPrincipal Financial and Accounting Officer, Chief Accounting Officer and Treasurer
Paula George CPADirector of Accounting and Operations and Assistant Corporate Controller
Leah R. NeufeldChief People Officer
Dr. Peter King Ph.D.Head of Discovery and Vice President
Dr. Praveen Nair Ph.D.Head of Translational Pharmacology and Vice President
Harold E. BrakewoodChief Business Officer

Latest SEC Filings

DateTypeTitle
Sep 9, 2025DNotice of Exempt Offering of Securities
Sep 8, 2025EFFECTNotice of Effectiveness
Sep 8, 2025424B3Prospectus
Sep 3, 2025S-3Registration statement under Securities Act of 1933
Aug 25, 20258-KCurrent Report
Aug 20, 2025EFFECTNotice of Effectiveness
Aug 13, 2025S-3Registration statement under Securities Act of 1933
Aug 13, 202510-QQuarterly Report
Aug 13, 20258-KCurrent Report
Jun 23, 2025424B5Filing